What is the contribution of molecular studies to the diagnosis of BCR-ABL- positive disease in adult acute leukemia? Am J Med 1994; 96: 133-138.Kantarjian H, Talpaz M, Estey E, Ku S, Kurzrock R (1994): What is the contribution of molecular studies to the diagno- sis of BCR-ABL-...
Although counterintuitive, incorporating a requirement for a negative MRD test in the definition of complete remission or of EFS might decrease the strength of the correlation between these end points and survival. If relapse was said to occur if there was a positive MRD test despite having <5% ...
ArticlePubMedCASGoogle Scholar Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.Ann Oncol. 2007;18:874–80....
4902 BCR-ABL expression level is the exclusive and irreplaceable marker for monitoring the response to treatment in patients with chronic myeloid leukemia (CML). CML therapy by tyrosine kinase inhibitors (TKIs) is very succesfull, nevertheless resistance to imatinib treatment develops in about 25 鈥 ...
What is the contribution of molecular studies to the diagnosis of BCR-ABL- positive disease in adult acute leukemia. Am J Med 1994; 96: 133-138.Kantarjian H, Talpaz M, Estey E, Ku S, Kurzrock R: What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive ...
BCR-ABL Fluctuation in Chronic Myeloid Leukemia (CML) Patients with Deep Molecular Response (MR): What is the Meaning of a Big Wave when You Test the Patients in Different Laboratories?Background: Imatinib (IM) is a first choice drug for treatment of chronic myeloid leukemia (CML), with a...